Literature DB >> 16807247

Solution structure and antiestrogenic activity of the unique C-terminal, NR-box motif-containing region of MTA1s.

Rajesh R Singh1, Kumaralal Kaluarachchi, Mingzhi Chen, Suresh K Rayala, Seetharaman Balasenthil, Jianpeng Ma, Rakesh Kumar.   

Abstract

Metastasis tumor-associated 1 short form (MTA1s) is a naturally occurring, alternatively spliced variant of MTA1 that functions as a repressor of estrogen receptor (ER) alpha transcriptional functions, at least in part by binding and sequestering ERalpha in the cytoplasm. A unique C-terminal 33-amino acid region containing a nuclear receptor (NR)-box motif (-LRILL-) mediates binding of MTA1s with ERalpha and is indispensable in this interaction. Here, we elucidated the solution structure of this 33-amino acid region by NMR spectroscopy. We found a predominance of the alpha-helical region toward the N-terminal region, which includes the NR-box motif. In silico docking and comparison studies showed similarities between the NR-box motif of MTA1s and a similar motif of coregulators, both in structure and mode of ERalpha binding. In MCF-7 breast cancer cells, the MTA1s peptide effectively repressed ERalpha transactivation function, as evidenced by the estrogen response element-luc assay and down-regulation of estrogen-induced genes. In mechanistic studies, we found that the antiestrogenic effects of the MTA1s peptide were due to its ability to compete with the coactivator recruitment to ERalpha. Furthermore, the peptide efficiently repressed estrogen-induced proliferation and anchorage-independent growth of MCF-7 cells. In addition, the MTA1s peptide blocked the progression of tumors formed by MCF-7 cells overexpressing an ERalpha coactivator in a xenograft-based assay. In brief, the characterization of structure and antiestrogenic activity of MTA1s peptide highlight its therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807247     DOI: 10.1074/jbc.M604444200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Xiaodong Sun; Peng Guo; Qunna Li; Masakiyo Sasahara; Yoko Ishii; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

Review 2.  MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer.

Authors:  Rajesh R Singh; Rakesh Kumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-09       Impact factor: 2.673

3.  CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer.

Authors:  Renjini Ambika Padmanabhan; Lini Nirmala; Megha Murali; Malini Laloraya
Journal:  Mol Endocrinol       Date:  2011-06-23

Review 4.  Nuclear receptor coregulators as a new paradigm for therapeutic targeting.

Authors:  Elaine Y Hsia; Michael L Goodson; June X Zou; Martin L Privalsky; Hong-Wu Chen
Journal:  Adv Drug Deliv Rev       Date:  2010-10-07       Impact factor: 15.470

Review 5.  The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications.

Authors:  Yasushi Toh; Garth L Nicolson
Journal:  Clin Exp Metastasis       Date:  2008-12-31       Impact factor: 5.150

6.  Pax6 represses androgen receptor-mediated transactivation by inhibiting recruitment of the coactivator SPBP.

Authors:  Julianne Elvenes; Ernst Ivan Simon Thomassen; Sylvia Sagen Johnsen; Katrine Kaino; Eva Sjøttem; Terje Johansen
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

7.  Residue correlation networks in nuclear receptors reflect functional specialization and the formation of the nematode-specific P-box.

Authors:  Marcelo Querino Lima Afonso; Leonardo Henrique França de Lima; Lucas Bleicher
Journal:  BMC Genomics       Date:  2013-10-25       Impact factor: 3.969

Review 8.  MTA family of coregulators in nuclear receptor biology and pathology.

Authors:  Bramanandam Manavathi; Kamini Singh; Rakesh Kumar
Journal:  Nucl Recept Signal       Date:  2007-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.